205 related articles for article (PubMed ID: 18006928)
1. Longitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: risk of neoplastic progression in Barrett's esophagus.
Siahpush SH; Vaughan TL; Lampe JN; Freeman R; Lewis S; Odze RD; Blount PL; Ayub K; Rabinovitch PS; Reid BJ; Chen C
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2387-95. PubMed ID: 18006928
[TBL] [Abstract][Full Text] [Related]
2. Serological levels of IGF-1 and IGFBP-3 in patients with Barrett's esophagus and esophageal adenocarcinoma: Longitudinal study.
Uchima H; Da Fieno A; Bonilla A; Melo-Borges J; Sánchez-Montes C; Cuatrecasas M; Córdova H; Elizalde I; Rakislova N; Gratacós-Ginès J; Bayarri C; Casanova G; Ginès À; Llach J; Balaguer F; Fernández-Esparrach G
Gastroenterol Hepatol; 2023 May; 46(5):360-368. PubMed ID: 36179948
[TBL] [Abstract][Full Text] [Related]
3. IGFBP-3 and IGFBP-10 (CYR61) up-regulation during the development of Barrett's oesophagus and associated oesophageal adenocarcinoma: potential biomarkers of disease risk.
Di Martino E; Wild CP; Rotimi O; Darnton JS; Olliver RJ; Hardie LJ
Biomarkers; 2006; 11(6):547-61. PubMed ID: 17056474
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor.
Chen C; Freeman R; Voigt LF; Fitzpatrick A; Plymate SR; Weiss NS
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2461-6. PubMed ID: 17164371
[TBL] [Abstract][Full Text] [Related]
5. Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma.
Dighe SG; Chen J; Yan L; He Q; Gharahkhani P; Onstad L; Levine DM; Palles C; Ye W; Gammon MD; Iyer PG; Anderson LA; Liu G; Wu AH; Dai JY; Chow WH; Risch HA; Lagergren J; Shaheen NJ; Bernstein L; Corley DA; Prenen H; deCaestecker J; MacDonald D; Moayyedi P; Barr H; Love SB; Chegwidden L; Attwood S; Watson P; Harrison R; Ott K; Moebus S; Venerito M; Lang H; Mayershofer R; Knapp M; Veits L; Gerges C; Weismüller J; Gockel I; Vashist Y; Nöthen MM; Izbicki JR; Manner H; Neuhaus H; Rösch T; Böhmer AC; Hölscher AH; Anders M; Pech O; Schumacher B; Schmidt C; Schmidt T; Noder T; Lorenz D; Vieth M; May A; Hess T; Kreuser N; Becker J; Ell C; Ambrosone CB; Moysich KB; MacGregor S; Tomlinson I; Whiteman DC; Jankowski J; Schumacher J; Vaughan TL; Madeleine MM; Hardie LJ; Buas MF
Carcinogenesis; 2021 Apr; 42(3):369-377. PubMed ID: 33300568
[TBL] [Abstract][Full Text] [Related]
6. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
7. IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity.
Doyle SL; Donohoe CL; Finn SP; Howard JM; Lithander FE; Reynolds JV; Pidgeon GP; Lysaght J
Am J Gastroenterol; 2012 Feb; 107(2):196-204. PubMed ID: 22146489
[TBL] [Abstract][Full Text] [Related]
8. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
[TBL] [Abstract][Full Text] [Related]
9. Epigenomic program of Barrett's-associated neoplastic progression reveals possible involvement of insulin signaling pathways.
Agarwal R; Jin Z; Yang J; Mori Y; Song JH; Kumar S; Sato M; Cheng Y; Olaru AV; Abraham JM; Verma A; Meltzer SJ
Endocr Relat Cancer; 2012 Feb; 19(1):L5-9. PubMed ID: 22194443
[No Abstract] [Full Text] [Related]
10. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells.
Yi HK; Kim SY; Hwang PH; Kim CY; Yang DH; Oh Y; Lee DY
Biochem Biophys Res Commun; 2005 May; 330(3):760-7. PubMed ID: 15809062
[TBL] [Abstract][Full Text] [Related]
11. IGF gene polymorphisms and breast cancer in African-American and Hispanic women.
Sarkissyan M; Mishra DK; Wu Y; Shang X; Sarkissyan S; Vadgama JV
Int J Oncol; 2011 Jun; 38(6):1663-73. PubMed ID: 21455574
[TBL] [Abstract][Full Text] [Related]
12. Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia.
Iravani S; Zhang HQ; Yuan ZQ; Cheng JQ; Karl RC; Jove R; Coppola D
Hum Pathol; 2003 Oct; 34(10):975-82. PubMed ID: 14608530
[TBL] [Abstract][Full Text] [Related]
13. Single nucleotide polymorphisms of IGFBP-3 gene and lung cancer risk in a Korean population.
Han SG; Park KH; Sung JS; Whang YM; Kim YJ; Shin ES; Lee JW; Lee HJ; Ryu JS; Choi IK; Seo JH; Kim YH
Lung Cancer; 2008 Nov; 62(2):152-61. PubMed ID: 18450319
[TBL] [Abstract][Full Text] [Related]
14. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer.
Gu F; Schumacher FR; Canzian F; Allen NE; Albanes D; Berg CD; Berndt SI; Boeing H; Bueno-de-Mesquita HB; Buring JE; Chabbert-Buffet N; Chanock SJ; Clavel-Chapelon F; Dumeaux V; Gaziano JM; Giovannucci EL; Haiman CA; Hankinson SE; Hayes RB; Henderson BE; Hunter DJ; Hoover RN; Johansson M; Key TJ; Khaw KT; Kolonel LN; Lagiou P; Lee IM; LeMarchand L; Lund E; Ma J; Onland-Moret NC; Overvad K; Rodriguez L; Sacerdote C; Sánchez MJ; Stampfer MJ; Stattin P; Stram DO; Thomas G; Thun MJ; Tjønneland A; Trichopoulos D; Tumino R; Virtamo J; Weinstein SJ; Willett WC; Yeager M; Zhang SM; Kaaks R; Riboli E; Ziegler RG; Kraft P
Cancer Epidemiol Biomarkers Prev; 2010 Nov; 19(11):2877-87. PubMed ID: 20810604
[TBL] [Abstract][Full Text] [Related]
15. Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease.
Su X; Colditz GA; Willett WC; Collins LC; Schnitt SJ; Connolly JL; Pollak MN; Rosner B; Tamimi RM
Int J Cancer; 2010 Jan; 126(1):180-90. PubMed ID: 19551864
[TBL] [Abstract][Full Text] [Related]
16. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
[TBL] [Abstract][Full Text] [Related]
17. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma.
Hao Y; Triadafilopoulos G; Sahbaie P; Young HS; Omary MB; Lowe AW
Gastroenterology; 2006 Sep; 131(3):925-33. PubMed ID: 16952561
[TBL] [Abstract][Full Text] [Related]
19. Toll-like Receptor 2 Signalling and the Lysosomal Machinery in Barrett's Esophagus.
Verbeek RE; Siersema PD; Vleggaar FP; Ten Kate FJ; Posthuma G; Souza RF; de Haan J; van Baal JW
J Gastrointestin Liver Dis; 2016 Sep; 25(3):273-82. PubMed ID: 27689189
[TBL] [Abstract][Full Text] [Related]
20. DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells.
Le H; Arnold JT; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2006 May; 290(5):E952-60. PubMed ID: 16368782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
